Capricor治疗 CAPR 深 沪
等待开盘 09-20 09:30:00 美东时间
4.99
-0.130
-2.54%
华盛通- 最 高5.26
- 今 开5.25
- 成交量 31.93万股
- 最 低 4.92
- 昨 收 5.12
- 总市值 1.57亿
- 52周最高 7.28
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 2.68
- 委 比 79.16%
- 总股本 3139.97万
- 历史最高 171.50
- 量 比 0.51
- 振 幅 6.64%
- 历史最低 0.88
- 每 手 1
- 风险率 1.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Capricor Therapeutics Secures Lucrative European Partnership
An announcement from Capricor Therapeutics ( ($CAPR) ) is now available. Capric...
09-17 21:48
Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel
Capricor Therapeutics (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku, a Japanese pharmaceutical company, for the commercialization and distribution in Europe of Capricor’s lead a...
09-17 21:41
Dyne stock tumbles 31% amid drug updates, management changes
Shares of Dyne Therapeutics (NASDAQ:DYN) fell 31% Tuesday after the company released new data from a clinical trial called DELIVER for its drug DYNE-251 in the treatment of Duchenne muscular dystrophy...
09-04 04:48
Caprock Mining Secures Funds Through Private Placement
Caprock Mining Corp (TSE:CAPR) has released an update. Caprock Mining Corp. has...
08-31 05:18
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 25% Plummet
To the annoyance of some shareholders, Capricor Therapeutics, Inc. (NASDAQ:CAPR...
08-08 19:02
Capricor Therapeutics Q2 2024 GAAP EPS $(0.35) Beats $(0.36) Estimate, Sales $3.971M Beat $3.664M Estimate
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.36) by 2.78 percent. The company reported quarterly sales of $3.971 million which beat
08-08 04:58
快讯 | Capricor Therapeutics的现金和现金等价物将足以覆盖其预期开支和资本需求至2025年第一季度。
Capricor Therapeutics- Co's Available Cash, Cash Equivalents Will Be Sufficient...
08-08 04:38
PepGen stock tumbles 25% following release of DMD drug data
PepGen (NASDAQ:PEPG) stock plunged 25% in post-market trading Tuesday after the company released data for its drug PGN-EDO51 in the treatment of Duchenne muscular dystrophy, or DMD. PepGen reported da...
07-31 07:37
Unveiling 6 Analyst Insights On Capricor Therapeutics
Analysts' ratings for Capricor Therapeutics (NASDAQ:CAPR) over the last quarter...
07-02 20:01
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40 price target.
07-02 18:40
